News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 24, 2022- Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection -
-
Feb 18, 2022Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022
-
Feb 17, 2022- Webcast to be Held at 8:00 am ET on February 24, 2022 -
-
Dec 14, 2021- Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects -
-
Nov 4, 2021- Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis -
-
Nov 1, 2021- Webcast to be Held at 8:00 am ET on November 4, 2021 -